- Open Access
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines
© Patties et al.; licensee BioMed Central Ltd. 2013
Received: 25 March 2013
Accepted: 7 May 2013
Published: 14 May 2013
Medulloblastoma (MB) is the most common malignant brain tumor in childhood with a 5-year survival of approximately 60%. We have recently shown that treatment of human MB cells with 5-aza-2’-deoxycytidine (5-aza-dC) reduces the clonogenic survival significantly. Here, we tested combinatorial effects of 5-aza-dC with other epigenetic (valproic acid, SAHA) and differentiation-inducing drugs (resveratrol, abacavir, retinoic acid) on human MB cells in vitro to intensify the antitumor therapy further.
Three human MB cell lines were treated with 5-aza-dC alone or in combination for three or six days. Metabolic activity was measured by WST-1 assay. To determine long-term reproductive survival, clonogenic assays were performed. Induction of DNA double-strand break (DSB) repair was measured by γH2AX assay.
The applied single drugs, except for ATRA, reduced the metabolic activity dose-dependently in all MB cell lines. Longer treatment times enhanced the reduction of metabolic activity by 5-aza-dC. Combinatorial treatments showed differential, cell line-dependent responses indicating an important impact of the genetic background. 5-Aza-dC together with resveratrol was found to exert the most significant inhibitory effects on metabolic activity in all cell lines. 5-aza-dC alone reduced the clonogenicity of MB cells significantly and induced DSB with no further changes after adjuvant administration of resveratrol.
The observed significant decrease in metabolic activity by combinatorial treatment of MB cells with 5-aza-dC and resveratrol does not translate into long-term reproductive survival deficiency in vitro. Further studies in animal models are needed to clarify the resveratrol-mediated anticancer mechanisms in vivo.
Medulloblastoma (MB) is the most common malignant brain tumor in childhood and accounts for 20% of such entities. It arises during embryonic development from neural precursor cells in the precerebellum or the dorsal brain stem. It is widely believed that genetic, gene regulatory, or epigenetic abnormalities give rise to tumor initiation and inhibit normal neuronal or glial differentiation in neural stem cells. MB standard therapy includes primary tumor resection followed by irradiation and/or chemotherapy. At the moment, therapy stratification depends on tumor histology, metastasis stage, and patient age. Patients belonging to the high-risk group and such with metastases receive a more intensive concomitant chemoradiotherapy compared to low-risk patients. Infants below 18 months do not obtain radiation therapy to avoid radiation-related adverse late effects, like neurocognitive and psychomotoric deficits, but receive a highly aggressive chemotherapy. With overall 5-year survival rates of approximately 60%, an improved antitumor strategy is urgently needed to further enhance the outcome of the moderate- and high-risk patients (90% of all MB patients). Especially in younger children, a reduction of treatment-induced adverse effects, by applying less toxic agents, is an ambitious aim in MB therapy optimization.
Epigenetic aberrations like HIC1, RASSF1a, or CASP8 promoter methylation, which are observed in most MBs (70–90%), lead to silenced tumor suppressor genes (TSG) and are responsible for the lack of cell cycle arrest and apoptosis in tumor cells. Hence, the application of epigenetic modulators in the treatment of MB might be a suitable approach to improve the standard therapy. Methyltransferase inhibitors like 5-aza-2’-deoxycytidine (5-aza-dC, decitabine) and histone deacetylase inhibitors (HDACi) like valproic acid (VPA) or SAHA are approved for the therapy of other diseases such as myelodysplastic syndromes, neurological disorders, or T-cell lymphoma. Application of epigenetic drugs in leukemia and carcinomas is currently tested in clinical studies. In addition, the low differentiation stage of MB cells constitutes also an attractive approach for MB therapy. The usage of differentiation-inducing drugs may induce neuronal or glial maturation in tumor cells and, therefore, eliminate their cancer-causing abilities. For instance, all-trans retinoic acid (ATRA) has already been used in differentiation therapy of leukemia patients. In vitro experiments with abacavir and resveratrol exhibited the drug-mediated induction of a more differentiated cell phenotype in MB cell lines[3–5]. Combination of nucleoside analogs like 5-aza-dC with HDACi might result in amplified effects as HDACi have been shown to suppress the alien nucleotide removal. Also, induction of differentiation might work much more successfully after reactivation of beforehand silenced differentiation-relevant genes.
In this study, we tested single and combinatorial effects of 5-aza-dC with other epigenetic drugs (VPA, SAHA) or differentiation inducers (resveratrol, abacavir, ATRA), as detailed below, on the metabolic activity and reproductive survival of human MB cell lines.
5-Aza-dC, a cytidine analog and methyltransferase inhibitor, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome since 2006. 5-Aza-dC is known to reactivate silenced TSG by demethylation of their promoter regions in MB and other tumor cells after incorporation into the DNA during the replication process[8–10]. DNA-integrated 5-aza-dC traps de novo methyltransferases (DNMT) and induces DNA damage including double-strand breaks (DSB)[11, 12]. We have recently shown that 5-aza-dC treatment of human MB cells reduces their vitality, proliferation rate, and clonogenic survival significantly. Others have described similar effects in leukemia and lung cancer cell lines[13, 14].
VPA, an HDACi, has already been established in the treatment of epilepsy and depression, and clinical trials for its application in HIV and cancer patients are ongoing. VPA leads to hyperacetylation of histone proteins resulting in activation of cell cycle arrest and apoptosis in human MB cells. In xenograft MB mouse models, it was shown that VPA alone reduces tumor growth and prolonges survival. It was also reported that combinatorial treatment with 5-aza-dC and VPA is able to diminish tumor initiation in a Ptch-deficient MB mouse model.
SAHA (vorinostat, Zolinza™) is the first HDACi approved by the FDA for cancer treatment. SAHA directly interacts with the catalytic domain of histone deacetylases. As a result, gene promoter-bound histones stay hyperacetylated and facilitate the selective transcription of genes. Additionally, SAHA exerts chemosensitizing effects in oral squamous cell carcinoma and medulloblastoma cells[20, 21].
Abacavir, a 2-deoxyguanine analog, is approved for HIV and AIDS therapy in the EU since 1999. Two ways of an abacavir-mediated reduction of telomerase activity are reported: 1) indirect, by incorporation into the DNA strand which leads to polymerization stop, and 2) direct, by downregulation of hTERT (human gene for telomerase reverse transcriptase) mRNA transcription. In recent years, abacavir attracted attention for cancer therapy for its ability to inhibit telomerase activity, which is known to be overexpressed in the vast majority of cancers. Also in 70% of MBs, telomerase activity is enhanced in contrast to normal cerebellum. It was previously shown that treatment of human MB cell lines with abacavir results in proliferation inhibition and neuronal differentiation.
ATRA is the prototype of differentiation therapy in cancer cells and, therefore, it is approved for treatment of acute promyelocytic leukemia (APL) in the EU since 1996. Inhibition of proliferation and induction of apoptosis and differentiation have been observed in many tumor cells including MB cells after treatment with ATRA[25–30].
Resveratrol, a plant polyphenol, is described to exhibit tumor-preventive as well as anticancer effects dependent on concentration, cell type, and microenvironment[31–33]. In MB cells, resveratrol has been shown to induce cell cycle arrest, apoptosis, and/or neuronal differentiation[4, 5, 34].
In this study, we show that the applied single mediators, except for ATRA, reduce the metabolic activity in all MB cell lines. In combinatorial treatments with the epigenetic modifier 5-aza-dC, resveratrol reveals the strongest decrease in metabolic activity, but it can not further reduce the 5-aza-dC-induced decrease of clonogenic survival.
5-Aza-2’deoxycytidine (decitabine, trade name Dacogen®), all-trans retinoic acid (ATRA), resveratrol, and valproic acid were purchased from Sigma-Aldrich (Munich, Germany). Abacavir hemisulfate was kindly provided from GlaxoSmithKline (Hamburg, Germany) and suberoylanilide hydroxamic acid (SAHA, vorinostat, trade name Zolinza®) from MSD (Haar, Germany). Stock solutions were prepared as follows and stored at - 20°C: 10 mM 5-aza-dC in PBS; 500 μM ATRA in 10% ethanol (stored at - 80°C); 500 μM resveratrol in 1% ethanol; 1 M valproic acid in PBS; 100 mM abacavir in PBS; 100 μM SAHA in 0.25% DMSO. Further work solutions were made in PBS and administered in equal dilutions to the cell medium. To exclude effects based on ethanol or DMSO applications, appropriate controls were implemented.
Cell lines and cell culture
The human MB cell line MEB-Med8a was kindly provided by Prof. T. Pietsch (Department of Neuropathology, University of Bonn Medical Centre, Bonn, Germany). The MB cell lines D283-Med and DAOY were purchased from ATCC cell biology collection (Manassas VA, USA). D283-Med and DAOY were maintained in MEM (Sigma-Aldrich, Munich, Germany) including 2 mM L-glutamine (Biochrom, Berlin, Germany), MEB-Med8a in DMEM with 4.5 g glucose (Lonza, Basel, Switzerland), all supplemented with 10% FCS (PAA, Yeovil, Somerset, UK), 100 U/ml penicillin, and 100 μg/ml streptomycin (Biochrom, Berlin, Germany) at 37°C and 5% CO2 unless otherwise noted.
Concentrations for the combinatorial treatment with 5-aza-dC
For clonogenic assays, cells were treated with/without 3 μM (D283-Med) or 5 μM (DAOY, MEB-Med8a) 5-aza-dC in cell culture flasks for three days. Subsequently, medium was renewed and supplemented with 5-aza-dC and 15 μM (D283-Med, DAOY) or 40 μM Resveratrol (MEB-Med8). After three days, cells were counted, seeded at three different cell densities in duplicates in 6-well cell culture plates, and normal medium without mediators was added. Ten to 14 days later, colonies were washed with PBS, fixed with ice-cold ethanol/acetone (1 : 1) for 10 min, stained with Giemsa solution (1 : 1 with distilled water) for 5 min, and washed with distilled water. Colonies with > 50 cells were counted indicating plating efficiency (PE). The ratio between PE of treated cells and PE of untreated cells represented the surviving fraction (SF) of clonogenic cells.
Statistic analyses of were performed using the parametric, one-way, and paired Student’s t-test with Microsoft Excel 2003 software. P-values ≤ 0.05 (*) were considered as statistically significant and p-values ≤ 0.001 (**) as highly statistically significant.
Detailed drug interaction analyses regarding synergistic or additive effects were conducted using the Bliss independence (BI) model which is based on the non-interaction theory. The BI model compares the estimates of the combined effects calculated on the individual drug effects with those obtained from the experiment. Therefore, the following equation was used: E i = E A × E B , where E i is the estimated amount of metabolic activity of the theoretical combination of substance A and B, and EA and EB are the experimental rates of metabolic activity of each drug alone. The interaction of both is described by the difference ΔE between the estimated and the observed rates of metabolic activity ΔE = E estimated − E observed . The non-parametric approach described by Prichard et al. was modified and used to calculate statistical significance of synergism. In each of the three independent experiments, the observed rates of metabolic activity were subtracted from the predicted values, and the average difference of each experiment was calculated. Statistically significant synergy was claimed when the average difference as well as its 95% confidence interval was positive.
Results and discussion
To determine submaximal concentrations for the inhibition of the metabolic activity of MB cells, we performed incubation experiments with the single drugs. The mean drug concentration of the three examined cell lines which inhibits the metabolic activity by 30% (IC30) was chosen for combination treatments with 5-aza-dC for three days (Table 1). The long-time reproductive cell survival of the combination showing the most promising results in metabolic inhibition was investigated and induction of DSB as a potential mechanism for cell death was evaluated.
Effects on metabolic activity (WST-1 assay)
Also, SAHA induced a concentration-dependent decrease of metabolic activity (Figure 2b). The IC 30 values were 60 nM ‒ 260 nM (MEB-Med8a, D283-Med). After simultaneous treatment with 5-aza-dC, the metabolic activity of D283-Med and DAOY cells was only slightly reduced, compared to 5-aza-dC alone. Similarly to 5-aza-dC/VPA treatment response, MEB-Meb8a cells exhibited a significant enhancement of metabolic activity after combined treatment with SAHA (Figure 3b). Corresponding to these cell line-specific findings, differential results have also been published showing minor effects in colon carcinoma cells, but significantly enhanced cell death in ovarian cancer and leukemia cells after combinatorial 5-aza-dC/SAHA treatment[38–40].
Treatment of MB cells with abacavir resulted in a dose-dependent reduction of metabolic activity (Figure 2c). Thereby, D283-Med revealed to be the most resistant among the examined cell lines showing an IC 30 value of 340 μM, whereas MEB-Med8a and DAOY cells exhibited IC 30 values of 70 μM and 150 μM. The higher resistance is possibly due to a higher expression of human telomerase reverse transcriptase (hTERT) in D283-Med cells compared to DAOY cells[3, 24]. Applying higher abacavir concentrations (350 μM to 750 μM, treated for 24 to 96 h), Rossi et al. reported that abacavir induces enhanced mortality in D283-Med cells, but differentiation and growth arrest in DAOY cells. We found here that simultaneous treatment with 5-aza-dC led to an additive response of two MB cell lines (DAOY, D283-Med) in metabolic activity (Figure 3c). This is the first time showing intensifying in vitro effects of an epigenetic modifier and a telomerase inhibitor on metabolic activity of tumor cells.
Retinoic acid treatment induced differential, cell line-specific effects: MEB-Med8a cells showed no response to ATRA; DAOY cells exhibited only a moderate reduction of metabolic activity with a maximum of 30%; and in D283-Med cells, a dose-dependent reduction of metabolic activity with up to 70% inhibition could be observed (Figure 2d). This goes along with findings of other groups[28, 30, 41]. In the highly sensitive D283-Med cell line, an ATRA-mediated caspase 3 induction followed by apoptosis has been reported. In contrast, DAOY cells showed only a moderate ATRA-induced enhancement of caspase 3 expression and apoptosis. The presence of OTX2 (orthodenticle homeobox 2), a homeobox protein acting as a transcription factor during brain development, seems to be necessary for ATRA-induced mortality of tumor cells. In accordance, enhanced OTX2 protein levels have been observed in the sensitive D283-Med cells, whereas the relatively resistant DAOY cells do not express OTX2. The combinatorial treatment with 5-aza-dC revealed no further effect in the ATRA-sensitive D283-Med cells but led to a significant increase of metabolic activity in DAOY cells compared to 5-aza-dC alone. The simultaneous treatment of the ATRA-resistant MEB-Med8a cells showed no 5-aza-dC-dependent effect on the ATRA responder status (Figure 3d). In contrast, Fu et al. reported a 5-aza-dC-induced hypomethylation of the hypermethylated CRABP-II (cellular retinoic acid-binding protein) gene promoter in ATRA-resistant MB cells leading to the expression of the afore-silenced gene. This affects the ATRA transport into the nucleus and lead to an ATRA-mediated cellular response in these MB cells. However, the lack of an ATRA response in MEB-Med8a after combined treatment with 5-aza-dC indicates that hypermethylation of the CRABP-II promoter is not responsible for ATRA resistance in this MB cell line.
As shown in Figure 2e, resveratrol (> 10 μM) led to a significant concentration-dependent reduction of metabolic activity in all three examined cell lines, possibly by inhibition of STAT3 (signal transducer and activator of transcription 3) expression and activity, which results in irreversible cell cycle arrest or apoptosis. The IC 30 values of 15 μM (D283-Med, DAOY) and 40 μM (MEB-Med8a) are within the concentrations of 40 μM, maximal achievable in blood serum after intravenous injection. The combined administration of resveratrol and 5-aza-dC showed a significant synergistic inhibition of 18% (MEB-Med8a), 41% (D283-Med) and 54% (DAOY) on metabolic activity versus 5-aza-dC alone (Figure 3e). The sensitive response of the TP53-mutated DAOY cell line might indicate a speculative role of resveratrol in the therapy of highly aggressive and therapy-resistant TP53-mutated MB tumors. Numerous studies, regarding the outcome of TP53-mutated MBs, which represents about 10% of all MBs, showed a 5-year event-free survival of 0%[43–47]. Interestingly, resveratrol has been shown to induce apoptosis p53-dependently and also p53-independently[48, 49].
Combinatorial effects of 5-aza-dC and resveratrol on clonogenicity and DSB repair
Combination of 5-aza-dC and differentiation-inducing or epigenetic mediators show promising antitumor effects on metabolic activity of MB cells. Cell line-specific results indicate an important impact of the genetic background, which is known to be extremely variable in MBs. Further insight in the acting mechanisms, especially of resveratrol, is needed to evaluate the full potential in antitumor therapy and to translate the synergistic effects on short-term metabolic activity into long-term reproductive survival deficiency.
- Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J: Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010, 468: 1095-1099. 10.1038/nature09587.View ArticleGoogle Scholar
- de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R: Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol. 2008, 10: 1040-1060. 10.1215/15228517-2008-059.View ArticleGoogle Scholar
- Rossi A, Russo G, Puca A, La MR, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F: The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Int J Cancer. 2009, 125: 235-243. 10.1002/ijc.24331.View ArticleGoogle Scholar
- Yu LJ, Wu ML, Li H, Chen XY, Wang Q, Sun Y, Kong QY, Liu J: Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia. 2008, 10: 736-744.View ArticleGoogle Scholar
- Wang Q, Li H, Wang XW, Wu DC, Chen XY, Liu J: Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett. 2003, 351: 83-86. 10.1016/j.neulet.2003.07.002.View ArticleGoogle Scholar
- Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA: HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One. 2008, 3: e2445-10.1371/journal.pone.0002445.View ArticleGoogle Scholar
- Fu YS, Wang Q, Ma JX, Yang XH, Wu ML, Zhang KL, Kong QY, Chen XY, Sun Y, Chen NN: CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells. Mol Oncol. 2012, 6: 48-61. 10.1016/j.molonc.2011.11.004.View ArticleGoogle Scholar
- Patties I, Jahns J, Hildebrandt G, Kortmann RD, Glasow A: Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Strahlenther Onkol. 2009, 185: 331-338. 10.1007/s00066-009-1956-1.View ArticleGoogle Scholar
- Hagemann S, Heil O, Lyko F, Brueckner B: Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011, 6: e17388-10.1371/journal.pone.0017388.View ArticleGoogle Scholar
- Li LH, Olin EJ, Fraser TJ, Bhuyan BK: Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Res. 1970, 30: 2770-2775.Google Scholar
- Santi DV, Norment A, Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 1984, 81: 6993-6997. 10.1073/pnas.81.22.6993.View ArticleGoogle Scholar
- Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD: DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008, 28: 752-771. 10.1128/MCB.01799-07.View ArticleGoogle Scholar
- Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL: Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer. 2008, 8: 128-10.1186/1471-2407-8-128.View ArticleGoogle Scholar
- Boivin AJ, Momparler LF, Hurtubise A, Momparler RL: Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs. 2002, 13: 869-874. 10.1097/00001813-200209000-00013.View ArticleGoogle Scholar
- Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC: Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther. 2005, 4: 1912-1922. 10.1158/1535-7163.MCT-05-0184.View ArticleGoogle Scholar
- Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, Blaney SM, Lau CC, Li XN: Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res. 2006, 12: 4687-4694. 10.1158/1078-0432.CCR-05-2849.View ArticleGoogle Scholar
- Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA: Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009, 69: 887-895. 10.1158/0008-5472.CAN-08-0946.View ArticleGoogle Scholar
- Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999, 401: 188-193. 10.1038/43710.View ArticleGoogle Scholar
- Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000, 97: 10014-10019. 10.1073/pnas.180316197.View ArticleGoogle Scholar
- Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol. 2007, 30: 1181-1188.Google Scholar
- Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, Fulda S: Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene. 2011, 30: 2275-2281. 10.1038/onc.2010.599.View ArticleGoogle Scholar
- Tendian SW, Parker WB: Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol Pharmacol. 2000, 57: 695-699.Google Scholar
- Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 1997, 33: 787-791. 10.1016/S0959-8049(97)00062-2.View ArticleGoogle Scholar
- Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK: Molecular analysis of PinX1 in medulloblastomas. Int J Cancer. 2004, 109: 309-314. 10.1002/ijc.11689.View ArticleGoogle Scholar
- Jones-Villeneuve EM, Rudnicki MA, Harris JF, McBurney MW: Retinoic acid-induced neural differentiation of embryonal carcinoma cells. Mol Cell Biol. 1983, 3: 2271-2279.View ArticleGoogle Scholar
- Sidell N, Sarafian T, Kelly M, Tsuchida T, Haussler M: Retinoic acid-induced differentiation of human neuroblastoma: a cell variant system showing two distinct responses. Exp Cell Biol. 1986, 54: 287-300.Google Scholar
- Webb M, Graham C, Walsh F: Neuronal differentiation of cloned human teratoma cells in response to retinoic acid in vitro. J Neuroimmunol. 1986, 11: 67-86. 10.1016/0165-5728(86)90076-7.View ArticleGoogle Scholar
- Gumireddy K, Sutton LN, Phillips PC, Reddy CD: All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Clin Cancer Res. 2003, 9: 4052-4059.Google Scholar
- Chang Q, Chen Z, You J, McNutt MA, Zhang T, Han Z, Zhang X, Gong E, Gu J: All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J Neurooncol. 2007, 84: 263-267. 10.1007/s11060-007-9380-9.View ArticleGoogle Scholar
- Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM: BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med. 2003, 9: 1033-1038. 10.1038/nm904.View ArticleGoogle Scholar
- Scott E, Steward WP, Gescher AJ, Brown K: Resveratrol in human cancer chemoprevention–choosing the 'right' dose. Mol Nutr Food Res. 2012, 56: 7-13. 10.1002/mnfr.201100400.View ArticleGoogle Scholar
- Whitlock NC, Baek SJ: The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer. 2012, 64: 493-502. 10.1080/01635581.2012.667862.View ArticleGoogle Scholar
- Muqbil I, Beck FW, Bao B, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS: Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Curr Pharm Des. 2012, 18: 1645-1654. 10.2174/138161212799958567.View ArticleGoogle Scholar
- Zhang P, Li H, Wu ML, Chen XY, Kong QY, Wang XW, Sun Y, Wen S, Liu J: c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. J Neurooncol. 2006, 80: 123-131. 10.1007/s11060-006-9172-7.View ArticleGoogle Scholar
- Bliss CI: The toxicity of poisons applied jointly1. Ann Appl Biol. 1939, 26: 585-615. 10.1111/j.1744-7348.1939.tb06990.x.View ArticleGoogle Scholar
- Prichard MN, Shipman C: A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14: 181-205. 10.1016/0166-3542(90)90001-N.View ArticleGoogle Scholar
- Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G: Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005, 29: 739-748. 10.1016/j.leukres.2004.11.022.View ArticleGoogle Scholar
- Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K: Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol. 2012, 188: 4441-4449. 10.4049/jimmunol.1103035.View ArticleGoogle Scholar
- Brodska B, Otevrelova P, Holoubek A: Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Mol Cell Biochem. 2011, 350: 71-80. 10.1007/s11010-010-0683-3.View ArticleGoogle Scholar
- Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011, 117: 4424-4438. 10.1002/cncr.26073.View ArticleGoogle Scholar
- Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW: Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res. 2005, 65: 919-924.Google Scholar
- Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007, 16: 1246-1252. 10.1158/1055-9965.EPI-07-0022.View ArticleGoogle Scholar
- Badiali M, Iolascon A, Loda M, Scheithauer BW, Basso G, Trentini GP, Giangaspero F: p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol. 1993, 2: 23-28.View ArticleGoogle Scholar
- Wang W, Kumar P, Wang W, Whalley J, Schwarz M, Malone G, Haworth A, Kumar S: The mutation status of PAX3 and p53 genes in medulloblastoma. Anticancer Res. 1998, 18: 849-853.Google Scholar
- Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res. 1994, 54: 5649-5651.Google Scholar
- Saylors RL, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, Brodeur GM: Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991, 51: 4721-4723.Google Scholar
- Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C: Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010, 28: 1345-1350. 10.1200/JCO.2009.23.5952.View ArticleGoogle Scholar
- Huang C, Ma WY, Goranson A, Dong Z: Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis. 1999, 20: 237-242. 10.1093/carcin/20.2.237.View ArticleGoogle Scholar
- Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, Chandra D: Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. J Biol Chem. 2011, 286: 28749-28760. 10.1074/jbc.M110.202440.View ArticleGoogle Scholar
- Radford IR: Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1986, 49: 611-620.View ArticleGoogle Scholar
- Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis. 2005, 26: 1978-1987. 10.1093/carcin/bgi165.View ArticleGoogle Scholar
- Yamamori T, DeRicco J, Naqvi A, Hoffman TA, Mattagajasingh I, Kasuno K, Jung SB, Kim CS, Irani K: SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010, 38: 832-845. 10.1093/nar/gkp1039.View ArticleGoogle Scholar
- Zhou J, Ahn J, Wilson SH, Prives C: A role for p53 in base excision repair. EMBO J. 2001, 20: 914-923. 10.1093/emboj/20.4.914.View ArticleGoogle Scholar
- Simsek G, Tokgoz SA, Vuralkan E, Caliskan M, Besalti O, Akin I: Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats. Eur Arch Otorhinolaryngol. 2012, 270: 1789-1793.View ArticleGoogle Scholar
- Subbiah U, Raghunathan M: Chemoprotective action of resveratrol and genistein from apoptosis induced in human peripheral blood lymphocytes. J Biomol Struct Dyn. 2008, 25: 425-434. 10.1080/07391102.2008.10507191.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.